Ovid Therapeutics Inc (OVID) - Total Liabilities
Based on the latest financial reports, Ovid Therapeutics Inc (OVID) has total liabilities worth $22.08 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Ovid Therapeutics Inc (OVID) long-term investment share to see how much of total assets are deployed in long-term investments.
Ovid Therapeutics Inc - Total Liabilities Trend (2014–2025)
This chart illustrates how Ovid Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Ovid Therapeutics Inc asset portfolio.
Ovid Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Ovid Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
MPS Limited
NSE:MPSLTD
|
India | Rs-5.96 Billion |
|
Irish Residential Properties
IR:IRES
|
Ireland | €589.47 Million |
|
First Foundation Inc.
NYSE:FFWM
|
USA | $10.99 Billion |
|
Suzhou Kelida Bldg &
SHG:603828
|
China | CN¥3.37 Billion |
|
Ningbo David Medical Device Co Ltd
SHE:300314
|
China | CN¥235.40 Million |
|
Qingdao Copton Technology Co Ltd
SHG:603798
|
China | CN¥169.56 Million |
|
Wajax Corporation
TO:WJX
|
Canada | CA$904.61 Million |
|
Masoval AS
OL:MAS
|
Norway | Nkr3.03 Billion |
Liability Composition Analysis (2014–2025)
This chart breaks down Ovid Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Ovid Therapeutics Inc net asset quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 12.39 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.11 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.10 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Ovid Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Ovid Therapeutics Inc (2014–2025)
The table below shows the annual total liabilities of Ovid Therapeutics Inc from 2014 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $20.27 Million | -15.32% |
| 2024-12-31 | $23.94 Million | -57.42% |
| 2023-12-31 | $56.23 Million | +144.55% |
| 2022-12-31 | $22.99 Million | +55.38% |
| 2021-12-31 | $14.80 Million | -54.18% |
| 2020-12-31 | $32.29 Million | +198.46% |
| 2019-12-31 | $10.82 Million | +22.34% |
| 2018-12-31 | $8.84 Million | +46.89% |
| 2017-12-31 | $6.02 Million | +61.28% |
| 2016-12-31 | $3.73 Million | +61.68% |
| 2015-12-31 | $2.31 Million | +1825.09% |
| 2014-12-31 | $119.95K | -- |
About Ovid Therapeutics Inc
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human or… Read more